1 |
CHAPMAN F A, NYIMANU D, MAGUIRE J J, et al. The therapeutic potential of apelin in kidney disease[J]. Nat Rev Nephrol, 2021, 17(12): 840-853.
|
2 |
SIMMONS J R, MURZA A, LUMSDEN M D, et al. Simultaneous ligand and receptor tracking through NMR spectroscopy enabled by distinct 19F labels[J]. Int J Mol Sci, 2019, 20(15): 3658.
|
3 |
FISCHER C. A patent review of apelin receptor (APJR) modulators (2014‒2019)[J]. Expert Opin Ther Pat, 2020, 30(4): 251-261.
|
4 |
MA Z, SONG J J, MARTIN S, et al. The Elabela-APJ axis: a promising therapeutic target for heart failure[J]. Heart Fail Rev, 2021, 26(5): 1249-1258.
|
5 |
READ C, NYIMANU D, WILLIAMS T L, et al. International Union of Basic and Clinical Pharmacology. CVII. Structure and pharmacology of the apelin receptor with a recommendation that Elabela/Toddler is a second endogenous peptide ligand[J]. Pharmacol Rev, 2019, 71(4): 467-502.
|
6 |
TATEMOTO K, HOSOYA M, HABATA Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor[J]. Biochem Biophys Res Commun, 1998, 251(2): 471-476.
|
7 |
MUGHAL A, O'ROURKE S T. Vascular effects of apelin: mechanisms and therapeutic potential[J]. Pharmacol Ther, 2018, 190: 139-147.
|
8 |
WANG Z, YU D, WANG M, et al. Elabela-apelin receptor signaling pathway is functional in mammalian systems[J]. Sci Rep, 2015, 5: 8170.
|
9 |
ANDERSON K, CNOTA J, JAMES J, et al. Prevalence of Noonan spectrum disorders in a pediatric population with valvar pulmonary stenosis[J]. Congenit Heart Dis, 2019, 14(2): 264-273.
|
10 |
SATO T, SATO C, KADOWAKI A, et al. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage[J]. Cardiovasc Res, 2017, 113(7): 760-769.
|
11 |
XU F, WU M, LU X, et al. Effect of Fc-Elabela-21 on renal ischemia/reperfusion injury in mice: mediation of anti-apoptotic effect via Akt phosphorylation[J]. Peptides, 2022, 147: 170682.
|
12 |
ZHANG Z, TANG J, SONG J, et al. Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling[J]. Free Radic Biol Med, 2022, 181: 130-142.
|
13 |
CHNG S C, HO L, TIAN J, et al. ELABELA: a hormone essential for heart development signals via the apelin receptor[J]. Dev Cell, 2013, 27(6): 672-680.
|
14 |
YANG P, READ C, KUC R E, et al. Elabela/toddler is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension[J]. Circulation, 2017, 135(12): 1160-1173.
|
15 |
YANG P, MAGUIRE J J, DAVENPORT A P. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system[J]. Trends Pharmacol Sci, 2015, 36(9): 560-567.
|
16 |
MURZA A, SAINSILY X, COQUEREL D, et al. Discovery and structure-activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions[J]. J Med Chem, 2016, 59(7): 2962-2972.
|
17 |
HO L, HO L, VAN DIJK M, et al. ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice[J]. Science, 2017, 357(6352): 707-713.
|
18 |
HO L, TAN S Y, WEE S, et al. ELABELA is an endogenous growth factor that sustains hESC self-renewal via the PI3K/AKT pathway[J]. Cell Stem Cell, 2015, 17(4): 435-447.
|
19 |
WANG Z, HUANG J. Apela promotes cardiomyocyte differentiation from transgenic human embryonic stem cell lines[J]. Appl Biochem Biotechnol, 2019, 189(2): 396-410.
|
20 |
XIE F, LV D G, CHEN L X. ELABELA: a novel hormone in cardiac development acting as a new endogenous ligand for the APJ receptor[J]. Acta Biochim Biophys Sin (Shanghai), 2014, 46(7): 620-622.
|
21 |
SCOTT I C, MASRI B, D'AMICO L A, et al. The G protein-coupled receptor Agtrl1b regulates early development of myocardial progenitors[J]. Dev Cell, 2007, 12(3): 403-413.
|
22 |
ZENG X X, WILM T P, SEPICH D S, et al. Apelin and its receptor control heart field formation during zebrafish gastrulation[J]. Dev Cell, 2007, 12(3): 391-402.
|
23 |
DIAKOWSKA D, WYDERKA R, KRZYSTEK-KORPACKA M, et al. Plasma levels of apelinergic system components in patients with chronic and acute coronary syndromes: a pilot study[J]. J Clin Med, 2021, 10(19): 4420.
|
24 |
MA Z, ZHAO L, MARTIN S, et al. Lower plasma elabela levels in hypertensive patients with heart failure predict the occurrence of major adverse cardiac events: a preliminary study[J]. Front Cardiovasc Med, 2021, 8: 638468.
|
25 |
WANG J, ZHOU Y, WANG Q, et al. Elabela: a novel biomarker for right ventricular pressure overload in children with pulmonary stenosis or pulmonary atresia with intact ventricular septum[J]. Front Cardiovasc Med, 2020, 7: 581848.
|
26 |
JIN L, PAN Y, LI Q, et al. Elabela gene therapy promotes angiogenesis after myocardial infarction[J]. J Cell Mol Med, 2021, 25(17): 8537-8545.
|
27 |
SAINSILY X, COQUEREL D, GIGUÈRE H, et al. Elabela protects spontaneously hypertensive rats from hypertension and cardiorenal dysfunctions exacerbated by dietary high-salt intake[J]. Front Pharmacol, 2021, 12: 709467.
|